TRPV1 hyperfunction in oxalate-mediated nephropathy is further evidenced by in vivo observations showing that chronic TRPV1 inhibition markedly reduced hyperoxaluria-induced tubular damage and CaOx crystal formation via inflammation. The gene discussed is TRPV1; the disease is Hyperoxaluria.